UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 | --- | --- | |---------------------------------------------------------------------------------------|-------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38942 ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact name of Registrant as specified in its Charter) Delaware 32-0595345 (State or other ...

Arcturus Therapeutics Holdings, Inc. (NASDAQ:ARCT) Q4 2019 Earnings Conference Call March 11, 2020 4:30 PM ET Company Participants Neda Safarzadeh - Director & Head, IR/Public Relations & Marketing Joseph Payne - Founder, President, CEO & Director Andrew Sassine - CFO & Director Padmanabh Chivukula - Founder, Chief Scientific Officer, COO & Secretary Conference Call Participants Madhu Kumar - R.W. Baird Whitney Ijem - Guggenheim Wangzhi Li - Ladenburg Yasmeen Rahimi - Roth Capital Partners Ed Arce - H.C. Wa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Common Stock, par value $0.001 per share ARCT The NASDAQ Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 | --- | --- | |------------------------------ ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2019 Results Conference Call August 15, 2019 4:30 PM ET Company Participants Neda Safarzadeh - Head, IR Joseph Payne - President and CEO Andy Sassine - CFO Dr. Pad Chivukula - Chief Scientific Officer and COO Conference Call Participants Ed Arce - H.C. Wainwright Kumar Raja - Brookline Capital Wangzhi Li - Ladenburg Thalmann Operator Greetings and welcome to the Arcturus Therapeutics Holdings Second Quarter 2019 Earnings Results Conference Call. At this t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Common Stock, par value $0.001 per share ARCT The NASDAQ Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38942 | --- | --- | |----------------------------------- ...